SADDLE RIVER, N.J.--(BUSINESS WIRE)--PDI, Inc. (NASDAQ: PDII), a provider of commercialization services to the biopharmaceutical industry, today announced that it has extended its sales services agreement with a top-10 pharmaceutical company through April 2009 to promote its leading anti-viral medication on a seasonal basis. The company will continue to utilize PDI’s Select Access team for an additional two seasons to reach primary care physicians and will be exclusive to pediatric targets. This initiative is expected to generate approximately $10.5M during the 2007-2008 promotional seasonal.
